Combined immune checkpoint inhibitor and chemotherapy is effective in a patient with ALK rearranged non-small cell lung cancer: a case report

Targeted therapies are validated to be efficient in non-small cell lung cancer (NSCLC) patients with driver gene mutations, but the emergence and development of immune checkpoint inhibitors (ICIs) in the last decades offers new insight into the therapeutic decisions of patients harboring driver gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Lexin, Hu, Hanguang, Li, Wen, Shen, Huahao, Xia, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798004/
https://www.ncbi.nlm.nih.gov/pubmed/35117552
http://dx.doi.org/10.21037/tcr.2019.12.39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798004/
https://www.ncbi.nlm.nih.gov/pubmed/35117552
http://dx.doi.org/10.21037/tcr.2019.12.39

Ejemplares similares